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ABSTRACT
Introduction Optimising glycaemic control in type 
1 diabetes (T1D) remains challenging. Flash glucose 
monitoring with FreeStyle Libre 2 (FSL2) is a novel alternative 
to the current standard of care self- monitoring of blood 
glucose (SMBG). No randomised controlled trials to date 
have explored the potential benefits of FSL2 in T1D. We aim 
to assess the impact of FSL2 in people with suboptimal 
glycaemic control T1D in comparison with SMBG.
Methods This open- label, multicentre, randomised (via 
stochastic minimisation), parallel design study conducted 
at eight UK secondary and primary care centres will aim 
to recruit 180 people age ≥16 years with T1D for >1 year 
and glycated haemoglobin (HbA1c) 7.5%–11%. Eligible 
participants will be randomised to 24 weeks of FSL2 
(intervention) or SMBG (control) periods, after 2- week of 
blinded sensor wear. Participants will be assessed virtually or 
in- person owing to the COVID-19 pandemic. HbA1c will be 
measured at baseline, 12 and 24 weeks (primary outcome). 
Participants will be contacted at 4 and 12 weeks for glucose 
optimisation. Control participants will wear a blinded sensor 
during the last 2 weeks. Psychosocial outcomes will be 
measured at baseline and 24 weeks. Secondary outcomes 
include sensor- based metrics, insulin doses, adverse events 
and self- report psychosocial measures. Utility, acceptability, 
expectations and experience of using FSL2 will be explored. 
Data on health service resource utilisation will be collected.
Analysis Efficacy analyses will follow intention- to- treat 
principle. Outcomes will be analysed using analysis 
of covariance, adjusted for the baseline value of the 
corresponding outcome, minimisation factors and other 
known prognostic factors. Both within- trial and life- time 
economic evaluations, informed by modelling from the 
perspective of the National Health Service setting, will be 
performed.
Ethics The study was approved by Greater Manchester 
West Research Ethics Committee (reference 19/NW/0081). 
Informed consent will be sought from all participants.
Trial registration number NCT03815006.
Protocol version 4.0 dated 29 June 2020.
INTRODUCTION
Type 1 diabetes mellitus (T1D) is one of the 
most common endocrine conditions. It is esti-
mated that approximately 415 million adults 
(5%–15% T1D) and 520 thousand children 
(95% T1D) worldwide suffer from diabetes.1 
Despite the availability of therapeutic options 
Strengths and limitations of this study
 ► Flash- UK is a multicentre randomised controlled trial 
of the novel FreeStyle Libre 2 flash glucose moni-
tor over a 6- month follow- up period assessing the 
impact on people living with type 1 diabetes and 
suboptimal glucose control, in comparison to self- 
monitoring of blood glucose, with a primary outcome 
of glycated haemoglobin.
 ► It is the first randomised study to assess the clin-
ical efficacy and health economic benefits of the 
Libre 2 device providing high quality data for UK 
policy- makers.
 ► The integration of a virtual assessment pathway into 
the trial design ensures eligible candidates are not 
restricted from participation owing to the COVID-19 
pandemic.
 ► A wide range of secondary outcomes including con-
tinuous glucose monitoring data and psychosocial 
outcomes will provide detailed insight into the im-
pact of this technology on people living with type 
1 diabetes.
 ► The study is open (unblinded) and conducted in UK 
National Health Service (NHS) only. Some findings 
from the study may only be applicable to UK NHS 
setting.
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such as self- monitoring of blood glucose (SMBG), struc-
tured education, rapid- acting insulin analogues and 
insulin pump therapy, glycaemic control in the majority 
of people with T1D remains suboptimal2 and they there-
fore remain prone to complications associated with high 
glucose levels, such as kidney failure and blindness.3 
In England, less than one- third of people with T1D 
achieve a glycated haemoglobin (HbA1c) level <7.5%.4 
Studies have shown a strong relationship between the 
frequency of SMBG and HbA1c, with the National Insti-
tute of Clinical Excellence recommending 4–10 checks 
per day.5 6 However, due to pain, inconvenience and the 
limited information a moment- in- time glucose value 
provides, finger- stick glucose monitoring remains a key 
barrier in achieving near normal glucose levels.
In 2014, the FreeStyle Libre Flash Glucose Moni-
toring System (FSL) (Abbott Diabetes Care, Oxon, UK) 
became available as a potential alternative to SMBG. The 
sensor utilises wired enzyme technology7 to continuously 
measure interstitial glucose levels. The arm- worn sensor is 
scanned using a reader or mobile phone app and provides 
information on current and previous glucose levels and 
trends. The IMPACT randomised controlled multicentre 
European trial was the largest study to evaluate the FSL8 
in 328 participants with well- controlled (HbA1c ≤7.5%, 
59 mmol/mol) T1D, one- third of whom used continuous 
subcutaneous insulin infusion (CSII) therapy. FSL use 
was associated with improvement in a range of glucose- 
related outcomes: a 38% reduction in time spent in 
hypoglycaemia (<3.9 mmol/L). There was an increase in 
glucose time in range but HbA1c was unchanged. The 
impact of FSL was also assessed in those with T2D on inten-
sive insulin therapy in a large multicentre randomised 
European study of 224 participants.9 Time in hypogly-
caemia (<3.9 mmol/L) reduced compared with controls 
by 43% but HbA1c was unchanged. In both randomised 
controlled trials treatment satisfaction was higher in FSL 
users and no device- related serious adverse events were 
reported, suggesting that flash glucose monitoring also 
offers a safe replacement to SMBG in those with diabetes 
on intensive insulin therapy.
Subsequently a range of observational studies have 
demonstrated benefits of FSL use for HbA1c and hypo-
glycaemia.10–15 Campbell et al evaluated the use of FSL as 
a replacement for SMBG in young people (4–17 years) 
(n=76, 58% CSII users, mean (SD) age 10.3 (4.0) years, 
baseline HbA1c 7.9 (1.0)% (63 mmol/mol), T1D dura-
tion 5.4 (3.7) years) with T1D in a single- arm European 
multicentre trial.16 After 2 weeks’ baseline masked wear, 
participants used FSL for 8 weeks. HbA1c significantly 
improved vs baseline, −0.4±0.6%, p<0.0001. However, a 
subsequent 6- month randomised controlled parallel- arm 
trial of the FSL in 64 participants aged 13–20 years with 
T1D and HbA1c ≥9% (≥75 mmol/mol) demonstrated 
no statistically significant difference between groups for 
changes in HbA1c at 6 months (adjusted mean −0.2% 
greater improvement for FSL [95% CI −0.9 to 0.5] 
(−2.1 mmol/mol (95% CI −9.6 to 5.4)); p=0.58).17 The 
discrepancy in findings between the observational and 
randomised controlled trials in the paediatric population 
highlights the importance of high- quality randomised 
trials to investigate the benefits of this technology. To date, 
although some are planned, there has been no published 
randomised controlled trial to demonstrate the impact of 
the FSL in adults with T1D and high HbA1c levels.18 19
More recently, in 2020, the FSL 2 (FSL2) launched in 
Europe. This is very similar to FSL except for an optional 
additional alarm to alert users when the glucose level 
falls outside their target range, in addition to improved 
senor accuracy.20 The FSL2 was launched in the United 
Kingdom in January 2021. To the best of our knowledge, 
no randomised controlled trials to assess the efficacy of 
the FSL2 system has been conducted or in progress. No 
economic evaluation assessing relative costs and benefits 
has been carried out in this patient group, nor has there 
been an assessment of patient acceptability. The purpose 
of the Flash UK study is to address this gap in the evidence 
and determine whether use of flash glucose monitoring 
with the FSL2 device will improve HbA1c over a 24- week 
randomised period compared with SMBG in adults with 
T1D and suboptimal glycaemic control.
METHODS AND ANALYSIS
Trial design
Flash- UK is an open, multicentre, randomised (1:1), 
parallel- group superiority trial, in adults and adolescents 
(16 years and older) with T1D and suboptimal glycaemic 
control (HbA1c 7.5% to 11% (59 to 97 mmol/mol), either 
on CSII or multiple daily injections (MDI), contrasting 
flash glucose monitoring using the FSL2 device with tradi-
tional finger- stick SMBG for 24 weeks. The study flow 
chart is outlined in figure 1.
Figure 1 Flash UK study flow chart. HbA1c, glycated 
haemoglobin; SMBG, self- monitoring of blood glucose.
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Study setting
Eight (one primary and seven secondary) care diabetes 
services from across England, UK.
1. Diabetes Centres within Manchester University 
Foundation Trust.
2. Diabetes Centres within University Hospitals of Derby 
and Burton National Health Service (NHS) Founda-
tion Trust
3. University Hospitals Birmingham NHS Foundation 
Trust.
4. Wolfson Adult Diabetes Endocrine Clinic, Cambridge 
Universities Hospitals, Cambridge.
5. Norfolk and Norwich University Hospital, Norwich.
6. Queen Alexandra Hospital, Portsmouth.
7. Ipswich Hospital, East Suffolk and North Essex NHS 
Foundation Trust, Ipswich.
8. Wareham Surgery (Wareham) and The Adam Practice 
(Poole), NHS England Primary Care general practi-
tioner Practices.
Eligibility criteria
The major eligibility criteria are age ≥16 years with T1D 
for at least 1 year and a HbA1c between 7.5% and 11%. 
The full criteria are available in box 1.
Interventions
FreeStyle Libre 2
This intervention is the CE marked FSL2 flash glucose 
monitoring device (Abbott Diabetes Care, Oxon, UK). 
The FSL2 glucose sensor is an arm worn sensor intended 
to last for 14 days. The component not directly attached to 
the patient is the handheld reader and/or mobile phone 
app which displays current and historical glucose data. 
Education and training about insertion and initiation of 
the sensor as well as how to use flash- glucose monitoring 
data for treatment optimisation is also provided. Encour-
agement is also provided to download data at home to 
identify pattern recognition. This session, designed to 
meet the needs of the individual, is conducted by a profes-
sional diabetes educator or a member of the study team.
Finger-stick SMBG
This is continuation of usual treatment. Additionally, 
encouragement will be given to use finger- stick glucose 
levels to optimise therapy and education about insulin 
dose adjustments using finger- stick glucose levels will also 
be provided. Participants in both arms will also receive 
training on sick day rules and dealing with hypo and 
hyperglycaemia as required.
Participants will be provided with an information leaflet 
following the training session, although the information 
provided will be tailored to the respective intervention. 
The leaflet provided in conjunction with the FSL2 will 
include sign- posting to educational videos provided 
by the Association of British Clinical Diabetologists 
(https:// abcd. care/ dtn/ education) and Bertie online ( 
www. bertieonline. org. uk) in conjunction with the finger- 
stick SMBG.
Outcomes
The FLASH- UK study is designed to assess an extensive 
array of clinical, psychosocial and usability outcomes 
(table 1). An outline of a dedicated health economic 
evaluation is provided below. The primary end point is 
HbA1c level at 24 weeks post randomisation. Sensor 
based outcomes comparing the FSL2 with SMBG will be 
assessed for the last 2 weeks of the intervention period. 
Prespecified sensor based outcomes include time in the 
target range (3.9–10 mmol/L), duration of hypogly-
caemia <3.5 mmol/L (63 mg/dL); <3.0 mmol/L (54 mg/
dL); <2.8 mmol/L (50 mg/dL), duration of hypergly-
caemia (>10 mmol/L (180 mg/dL), and >16.7 mmol/L 
(>300 mg/dL) and glucose variability (SD and coefficient 
Box 1 Key inclusion and exclusion criteria
Inclusion criteria
1. The participant is ≥16 years old.
2. The participant has type 1 diabetes, as defined by WHO for at least 
1 year or is confirmed C- peptide negative if duration of diabetes is 
<1 years.
3. Participant is treated with insulin pump or multiple daily injection for 
at least 12 weeks and no plans to change treatment modality during 
next 28 weeks.
4. The participant is literate in English for safe study conduct.
5. Screening glycated haemoglobin ≥7.5% (58.5 mmol/mol) and ≤11% 
(97 mmol/mol) based on analysis from local, central or third party 
external laboratory.
6. The participant is willing to wear study glucose sensor and scan for 
glucose levels at regular intervals.
7. The participant is willing to follow study- specific instructions and 
improve glucose control.
8. Female participants of childbearing age should be on effective con-
traception or not sexually active/no plans for pregnancy.
Exclusion criteria
1. Non- type 1 diabetes mellitus including those secondary to chronic 
disease.
2. Any other physical disease or people with known severe mental 
illness (psychotic disorder, bipolar disorder, dementia, substance 
and alcohol dependence, learning disabilities, depression with ac-
tive suicidal ideation) which are likely to interfere with the nor-
mal conduct of the study and interpretation of the study results as 
judged by the investigator.
3. Current users of real- time glucose monitoring sensors or flash- 
glucose monitoring for more than 4 weeks within last 12 weeks.
4. Initiation of medications/treatments known to interfere with glu-
cose metabolism (eg, metformin, SGLT2 inhibitors, GLP-1 agonists, 
pramlinatide) within the last 6 weeks or planning to start these 
medications within the next 6 months (patients on stable treatment 
is not an exclusion) or current or planned glucocorticoid use other 
than inhaled/topical use.
5. Known or suspected allergy against insulin.
6. Severe visual impairment.
7. Complete loss of hypoglycaemia awareness.
8. Patient receiving dialysis/predialysis based on history.
9. More than one episode of severe hypoglycaemia as defined by 
American Diabetes Association30 in preceding 24 weeks.
10. Pregnancy, planned pregnancy in the next 8 months or breast 
feeding.
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of variation). All the sensor based metrics will also be 
analysed separately for daytime (7:00–23:00 hours) and 
night- time (23:00–7:00 hours) in addition to the 24- hour 
period. Insulin usage data will be compared between 
the two arms. Harms outcomes include the frequency of 
severe hypoglycaemic episodes as defined by American 
Diabetes Association, frequency of significant ketosis 
events (plasma ketones >3 mmol/L) and the nature and 
severity of other adverse events. Information on any other 
antidiabetes therapy will be collected.
Questionnaires (table 1) will be employed at base-
line and the end of the study to evaluate participants’ 
responses in terms of quality of life, diabetes distress, 
needle burden, disordered eating, depression and 
diabetes treatment satisfaction using EQ- 5DL- 5L ques-
tionnaire, Type 1 Diabetes Distress Scale, Diabetes Fear 
of Injecting and Self- testing questionnaire, Diabetes 
Eating Problem Survey, Diabetes Treatment Satisfaction 
Questionnaire, Patient Health Questionnaire-9 and The 
Glucose Monitoring Satisfaction Survey. Hypoglycaemia 
burden will be assessed using Clarke questionnaire and 
Gold score.
Participant timeline and data collection
The study will consist of six visits for those in the FSL2 arm 
and seven visits in the SMBG arm. Visits 1 and 2 can be 
conjoined. The study flow chart is shown in figure 1. Key 
activities undertaken during each study visit are shown in 
table 2.
Due to the COVID-19 pandemic all study visits can 
be conducted either face to face or virtually (supported 
by telephone and videoconferencing as appropriate) as 
indicated in the approved study advertisement and partic-
ipant information sheet. At visit 1, following informed 
written consent (model consent form and patient infor-
mation sheet in online supplemental material) by trained 
Table 1 Secondary outcomes
Category Outcomes Assessment time point
HbA1c based HbA1c
HbA1c ≤53 mmol/mol (7.0%) (yes/no)
HbA1c ≤59 mmol/mol (7.5%) (yes/no)
Reduction in HbA1c ≥5.5 mmol/mol (0.5%) from baseline 
(yes/no)
Reduction in HbA1c ≥11 mmol/mol (1.0%) from baseline (yes/
no)
Baseline and 12 weeks
Baseline, 12 weeks and 24 weeks
Baseline, 12 weeks and 24 weeks
Baseline, 12 weeks and 24 weeks
Baseline, 12 weeks and 24 weeks
Sensor based (glucose) Time spent in the target glucose range 3.9–10.0 mmol/L 
(70–180 mg/dL)
Time spent below target glucose (<3.9 mmol/L) (<70 mg/dL), 
<3.5 mmol/L (63 mg/dL), <3.0 mmol/L (54 mg/dL); <2.8 mmol/L 
(50 mg/dL)
Time spent above target glucose (10.0 mmol/L) (180 mg/dL), 
>16.7 mmol/L) (300 mg/dL)
Average glucose, SD, coefficient of variation
AUC of glucose below 3.0 mmol/L (54 mg/dL)
Baseline and 24 weeks
Non- sensor based 
(clinical)
Daily average total insulin dose
Daily average basal insulin dose
Daily average bolus dose
Average number of boluses of rapid acting insulin per day
Frequency of severe hypoglycaemic episodes as defined by 
American Diabetes Association
Frequency of significant ketosis events (plasma ketones 
>3 mmol/L)
Nature and severity of other adverse events
Baseline, 12 weeks and 24 weeks
Psychosocial Type 1 Diabetes Distress Scale
Quality of Life (EQ- 5D- 5L)
Patient Health Questionnaire
Diabetes fear of injecting and self‐testing questionnaire
The revised Diabetes Eating Problem Survey
Baseline and 24 weeks
Process evaluation 
(utility and acceptability)
FSL2 device utilisation data, including: average no of scans 
per day (7:00–23:00 hours), per night (23:00–7:00 hours) and 
over the full 24- hour period; average no of days of usage per 
week for the full 24 weeks intervention
Continuous (FSL arm only)
Number of finger- stick glucose level tests per day Continuous
Diabetes Treatment Satisfaction Questionnaire
Glucose Monitoring Satisfaction Survey
Baseline and 24 weeks
AUC, area under the curve; FSL2, FreeStyle Libre 2; HbA1c, glycated haemoglobin.
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members of the research team, medical and diabetes 
history will be recorded including presence of diabetes 
complications, hypoglycaemia burden including the use 
of Clarke and Gold questionnaires, use of concomitant 
diabetes medications, ethnicity, body weight and height 
measurement; demographic data, insulin therapy, occu-
pation and educational attainment, any history of disor-
dered eating or needle phobia, previous participation in 
structured education, carbohydrate counting status, use 
of bolus calculator and patient self- report psychosocial 
questionnaires will be completed. Blood samples will be 
taken to measure HbA1c.
At visit 2, the FSL Pro blinded continuous glucose 
monitoring (CGM) device will be inserted, to be worn for 
2 weeks. For participants on the virtual pathway, partic-
ipant will be taught to self insert the sensor. At visit 3, 
participant adherence/tolerance of using the flash- CGM 
over the preceding 14 days will be assessed. To proceed 
to randomisation at least 10 of 14 days blinded CGM data 
must be available. Those who have <10 days data will be 
provided with a new FSL pro sensor and reader to obtain 
the minimum data requirements prior to randomisa-
tion or discontinue from trial participation if there is a 
continued adverse reaction to the sensor adhesive.
Participants will be followed up at 4, 12 and 24 weeks 
postrandomisation (±2 weeks). At these visits glucose data 
will be downloaded and participant diaries which collect 
information on insulin doses and carbohydrate intake 
in last 5 days will be collected. Participants in the virtual 
pathway will be encouraged to upload data from home. 
Blood tests for HbA1c will also be performed at 12 and 24 
weeks after randomisation. Those in the SMBG group will 
attend an additional visit at 22 weeks to have the blinded 
CGM sensor fitted to be worn from 22 to 24 weeks. At 
24 weeks, body weight measurement will be made where 
possible and the participant will be asked to complete 
questionnaires. In addition, participants in the FSL2 
arm will be asked to complete a questionnaire exploring 
expectations and experience of using FSL2 during the 
study. Healthcare resource use in primary and secondary 
healthcare settings will also be collected at 24 weeks.
Adverse events will be routinely collated at study visits. 
The independent data monitoring committee (IDMC) 
will be informed of all serious adverse events and any 
unanticipated adverse device effects that occur during 
the study and will review compiled adverse event data at 
periodic intervals.
Sample size
The target effect size (minimally clinically important 
HbA1c difference) of 0.4% was chosen as this is consis-
tent with other relevant trials (0.5% in REPOSE,21 0.4% 
in DIAMOND,22 0.3% in GOLD23). To achieve 90% 
power using an independent- sample t- test for 24 week 
HbA1c values (2- tail alpha=0.05, power=0.80, effect 
size=0.4%, SD=0.8%,23 ie, standardised effect size=0.5), 
128 participants with primary outcome data are required. 
This is inflated to a target of 150 randomised (assuming 
maximum 15% attrition) and up to 180 recruited (to 
allow for prerandomisation losses). The use of analysis 
of covariance (ANCOVA) with adjustment for baseline 




Start relative to previous/next 
visit/activity (+/- 2 weeks of 
planned visit date)
Visit 1 Recruitment and Screening visit: Consent
HbA1c, baseline bloods, baseline questionnaires
−2 to −3 weeks –
Visit 2 Blinded flash glucose monitor insertion −2 weeks Within 1 to 2 weeks of visit 1. 
Can coincide with visit 1
Visit 3 Adherence assessment &and
Randomisation
FSL2/Self- monitoring of glucose initiation
 ► Education
0 weeks After 2 weeks of visit 2
Visit 4 Review data/optimisation
Collect participant diary
+4 weeks After 4 weeks of visit 3
Visit 5 Review data/optimisation. Data download
 ► HbA1c
 ► Collect participant diary
+12 weeks After 8 weeks of visit 5
Visit 6 Blinded flash glucose monitor insertion (extra visit 
in SMBG arm)
+22 weeks After 10 weeks of visit 5
Visit 7 End of self- monitoring intervention arm
 ► HbA1c.
 ► Questionnaires
 ► Collect participant diary
+24 weeks 2 weeks after visit 6
FSL2, FreeStyle Libre 2; HbA1c, glycated haemoglobin; SMBG, self- monitoring of blood glucose.
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values of HbA1c and other minimisation factors should 
increase power.
Recruitment
Participants will be identified by treating clinicians in 
each centre and participant information sheet provided. 
The first study site was activated on the 20 December 
2019 and first participant was recruited on the 9 January 
2020. Each site will each aim to recruit between 14 and 30 
participants up to a total of 180 participants. The study 
has been advertised via social media and through the offi-
cial trial website (https:// sites. manchester. ac. uk/ flash/), 
providing those who do not usually attend study centres 
to have the opportunity to participate. As of 31 January 
2021, 109 participants had been randomised. It is antic-
ipated that recruitment will be completed by 30 April 
2021. In the event that a participant meets withdrawal 
criteria, sites will engage with participants to seek their 
verbal agreement to volunteer their continued participa-
tion for HbA1c time points (post randomisation) and exit 




Allocation to one of the two intervention arms (24 weeks 
use of flash glucose monitoring or 24 weeks use of conven-
tional finger- stick SMBG) will use stochastic minimisa-
tion (factors: study centre, baseline HbA1c (7.5%–9.0%; 
>9.0%–11%), treatment modality (MDI; CSII), prior 
participation in structured education course (yes; no) 
and current use of bolus calculator (yes; no)).
Allocation concealment mechanism and its implementation
Allocation will be implemented using the web- based 
Sealed Envelope software (Sealed Envelope, London, 
UK) randomisation system. This will be independently 
managed by Manchester Clinical Trials Unit (MCTU) 
staff. Participants will have their pseudonymised regis-
tration details entered into the randomisation system by 
delegated recruitment site research teams who will also 
confirm participant eligibility; only then will the system 
generate an email confirmation with their allocation.
Blinding (masking)
The trial is fully open. It is not possible to blind inves-
tigators or participants to the delivery or receipt of the 
intervention; data collectors and statisticians are also 
unblinded to treatment allocations.
Laboratory analysis
Blood samples for the measurement of HbA1c levels will 
be taken at three different time points: screening, 12 and 
24 weeks. This can be completed using the local labora-
tory (face- to- face clinic) or at home where the participant 
will collect a capillary blood sample using a validated 
home self- test kit (TDL TINY) and send in a prepaid 
envelope to The Doctors Laboratory (London, UK).
Data management
Confidentiality of participant data shall be observed at all 
times during the study. Personal details for each partici-
pant taking part in the research study and linking them 
to a unique identification number will be held locally 
on a study screening log in the Investigator Site File at 
each of the investigation centres. The study identifica-
tion number will be used on the case report forms,on 
all the blood samples that are collected throughout the 
study and FSL 2 and FSL Pro data submitted to study- 
specific Libreview database ( Libreview. com). Names and 
full addresses will not be used. Electronic data will be 
stored on password- protected computers. Only members 
of the research team and collaborating institutions will 
have password access to the anonymised electronic data. 
Paper copies of the data will be stored for 15 years. Direct 
access to the source data will be provided for monitoring, 
audits, REC review during and after the study. The fully 
anonymised data may be shared with third parties (EU or 
non- EU based) for the purposes of advancing manage-
ment and treatment of diabetes. Standard procedures 
agreed by the MCTU, chief investigator (CI) and clinical 
principal investigators are in place for data review, data-
base cleaning and issuing and resolving data queries.
Analysis
Statistical methods
All efficacy and safety analyses will be conducted following 
the ITT principle in which all randomised participants 
are analysed in their allocated treatment group whether 
or not they receive their randomised treatment. All 
baseline, 12- week and 24- week outcome data will be 
presented descriptively, both overall and within treatment 
group, using mean (SD), median (IQR) or frequency 
(percentage), as appropriate. All statistical tests will use 
a two- sided significance level of 5% (unless otherwise 
specified). All CIs will be presented at a level of 95% and 
will be two sided. All statistical analyses will be performed 
using Stata IC 15 (StataCorp).
The primary outcome analysis will evaluate between 
group differences in HbA1c levels at the end of the 24- week 
treatment period. An ANCOVA model will be used, with 
24- week HbA1c as the outcome and trial arm effect as 
the focus, and with adjustment for baseline HbA1c, and 
the other baseline variables included in the minimisa-
tion allocation algorithm as covariates. If more than 10% 
HbA1c data are missing at 24 weeks (or a >10% differ-
ence between missing data percentages in the two arms) 
multiple imputation will be used in order to implement a 
more complete ITT analysis of the substantive ANCOVA 
model (otherwise this will be performed as a sensitivity 
analysis, with a complete- case analysis used as the primary 
analysis). The imputation model will include baseline 
and 12- week HbA1c, all the baseline variables used in the 
outcome model and any other recorded variables found 
to be predictive of missingness in the 24- week outcome in 
exploratory analyses (via a logistic regression model, with 
terms included using a 10% significance level). Sensitivity 
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analyses will be performed to (1) examine robustness 
of how missing data are handled, (2) examine efficacy 
of treatment through Complier- Adjusted Causal Effect 
modelling, (3) examine impact of data collected outside 
the visit window and (4) examine potential impact of 
COVID-19 on the primary outcome.
Quantitative secondary outcomes will also be analysed 
using ANCOVA and binary secondary outcomes will be 
analysed using logistic regression. In each case, the anal-
ysis will be adjusted for the baseline value of the outcome 
and the adjustment factors used in the model for HbA1C. 
Harms data will be reported descriptively as frequencies 
and percentages (%), both overall and by intervention 
arm.
Subgroup analysis will be performed by the addi-
tion of interactions between intervention arm and 
the subgrouping factor. All subgroup analyses will be 
performed separately. Planned subgroups are: baseline 
HbA1c; treatment modality; prior participation in struc-
tured education course; age group; education level; hypo-
glycaemia unawareness; deprivation index quintile; sex; 
ethnic group.
Further sensitivity and/or subgroup analyses will be 
performed as appropriate. These together with fuller 
details of the analyses proposed above, and any additional 
analyses, will be included in a full Statistical Analysis Plan 
that will be approved by the Trial Steering Committee 
(TSC) prior to any analysis of the outcome data.
Economic analysis
The economic evaluation will determine the difference 
in costs and outcomes generated by the FSL2 device 
compared with SMBG. The economic evaluation will be 
conducted from the perspective of NHS/Personal Social 
Services (PSS) following standard quality design and 
reporting criteria.24
A within- trial cost–utility analysis will compare differ-
ences in total costs and differences in quality of life using 
QALYs derived from the EQ- 5D- 5L. QALYs will be calcu-
lated by attaching available utility weights to the health 
states generated from the EQ- 5D- 5L, using area under 
the curve methods with an assumption of a linear change 
between time points, controlling for baseline. Person- 
level costs will be generated for each person in the FSL2 
device and SMBG arms from a combination of trial- based 
resource use with published unit costs, allowing compar-
ison in terms of costs to NHS and PSS.25 Costs will be 
compared between the two groups using non- parametric 
methods.
Modelling the potential effect of the intervention on 
costs and outcomes beyond the trial period will provide a 
better idea of overall impact as the benefits of controlling 
HbA1c are likely to be seen after the endpoint of the 
trial. Therefore, we will carry out an economic evaluation 
informed by modelling to estimate longer- term benefits 
and costs, from an NHS/PSS perspective.
A commercially available cost- effectiveness model, the 
IMS Centre for Outcomes Research and Effectiveness 
diabetes model V.8.5 (IMS Health, Danbury, Connecticut, 
USA), will be used for this economic evaluation. The 
model consists of 15 submodels designed to simulate 
diabetes- related complications, non- specific mortality 
and costs over time. It also incorporates the costs and 
effects of hypoglycaemia, so is particularly well suited to 
this study. Two major validation papers on the IMS Core 
Diabetes Model (CDM) have been published to date.26 27 
The IMS CDM has also been used in a UK- based recent 
health technology assessment of CGM commissioned 
by National Institute for Health and Care Excellence 
(NICE).28
Incremental cost- effectiveness ratios will be calculated in 
the event of the intervention having either higher costs and 
better outcomes or lower costs and worse outcomes (no 
scenarios of dominance, based on QALYs and trial primary 
outcome). The base case analysis will estimate the mean 
costs and QALYs across the treatment arms. The overall 
impact of uncertainty will be assessed by generating cost- 
effectiveness planes from bootstrapped resamples, and 
distributional assumptions about the transition probabili-
ties, costs and utility values will be made. Cost- effectiveness 
acceptability curves will be constructed to show the proba-
bility that the intervention is cost- effective for different will-
ingness to pay (WTP) thresholds. Incremental economic 
analysis using the IMS CORE model will require the 
model’s time horizon to be set to 80 years, which approx-
imates to a lifetime horizon. All costs and effects will be 
discounted by 3.5%, as per NICE guidance.25 29
Process evaluation
The process evaluation will be undertaken to explain 
discrepancies between expected and observed outcomes, 
to understand how context influences outcomes, and 
to provide insights to aid implementation. Specifically, 
we will investigate whether treatment is consistent with 
the behavioural change theories, which underpin it and 
contextual factors have affected implementation. Process 
evaluation will use a pipeline logic model, showing 
causal links between resources, activities and outcomes, 
integrating the National Institute for Health Behaviour 
Change Consortium’s approach to treatment fidelity30 and 
a modified version of Linnan and Steckler’s framework for 
process evaluation.31 We will describe context qualitatively 
and take a mixed methods approach to characterising 
recruitment, reach, dose delivered/received and fidelity, 
with triangulation between data sources.32 Free- text 
response questionnaires will be completed by interven-
tion designers, health professionals and trial participants, 
and analyses combined with trial data, including FSL2 
device utilisation and SMBG data which will be analysed 
descriptively (including the use of appropriate graphical 
representation), within arms where appropriate, will be 
synthesised and findings triangulated appropriately.
Study management
Trial management group
Trial management group comprising the CI, coinves-
tigators, trial managers, trial statistician, trial health 
8 Wilmot EG, et al. BMJ Open 2021;11:e050713. doi:10.1136/bmjopen-2021-050713
Open access 
economist, monitor and data manager will meet quarterly 
to discuss the operational aspects of the study.
Trial steering committee
TSC with an independent chair has been appointed. Inde-
pendent membership of the TSC includes two clinical 
members (including the chair), two service users, health 
economist and statistician; non- independent members 
are CI and statistician coinvestigator (only Statistician 
voting). Other members of the study team including the 
Sponsor are invited to TSC meetings as observers only.
Independent data monitoring committee
An IDMC comprising a clinical chair, another clinical 
expert and a statistician has been appointed. The IDMC 
will be informed of all serious adverse events and any 
unanticipated adverse device effects/events that occur 
during the study. The IDMC will review compiled adverse 
event data at periodic intervals. The IDMC will report to 
the TSC any safety concerns and recommendations for 
suspension or early termination of the investigation.
Study monitoring
A detailed risk assessment was completed by MCTU and 
approved by the sponsor. The procedures, source data 
transfer modalities and anticipated frequency for moni-
toring are documented in the monitoring plan. Copies 
of the risk assessment and the monitoring plan will be 
stored in the Trial Master File. The MCTU study monitor 
will be fully independent of both the sponsor and site 
principal investigators.
Authorised representatives of sponsor, regulatory 
authority or an Ethics Committee may perform audits or 
inspections at the recruiting centres, including source 
data verification.
Any substantial/non- substantial amendments will be 
managed by the CTUs following an approved quality 
standard operating procedure. Favourable outcomes will 
be conveyed to participating sites for implementation 
following local R&D.
Patient and public involvement
During the grant application process the study protocol 
received input from several patient groups from 
Manchester, Derby and Cambridge as well as the INPUT 
patient advocacy group. One of the study investigators 
also has T1D as do two members of the TSC.
ETHICS AND DISSEMINATION
The study will be conducted in accordance with the 
Declaration of Helsinki Ethical Principles for Medical 
Research involving Human Subjects (October 2000). 
It was approved by Greater Manchester West Research 
Ethics Committee on 21/03/2019REC reference 19/
NW/0081. All participants will be provided with oral and 
written information about the trial, including the most 
common AEs, and the procedures involved in the study 
before obtaining written informed consent. The study 
results will be communicated to trial participants and 
disseminated in peer- review publications and through 
conference presentations. The data sharing plan is avail-
able in online supplemental appendix 1.
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